Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)
Clinical trial NCT03474133 · UNKNOWN
Trial details
- NCT number
- NCT03474133
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-14
- Primary completion
- 2023-10-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.